Authors: Lee C
Published Date October 2013 Volume 2013:7 Pages 1223 - 1233
DOI: http://dx.doi.org/10.2147/DDDT.S40310
Received: 29 July 2013
Accepted: 29 August 2013
Published: 16 October 2013
Choongho Lee
College of Pharmacy, Dongguk University-Seoul, Goyang, Republic of Korea
Abstract: Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma. It has been a tremendous burden on global health care systems. With the advent of a number of new direct-acting and host-targeting antiviral agents, current interferon-a- and ribavirin-based HCV therapy has started to move towards an interferon-sparing or even interferon-free strategy. In this regard, a recently identified NS5A inhibitor, daclatasvir, showed a great promise in clinical trials as another new class of direct-acting anti-HCV therapeutics, with a distinct mechanism of action. In this review, a variety of preclinical as well as clinical proof-of-concept studies of daclatasvir, including the studies of its discovery, mechanism of action, viral resistance, and host polymorphism profiles are reviewed. In addition, a role of daclatasvir in the future therapy for HCV patients is discussed briefly.
Keywords: hepatitis C virus, nonstructural protein 5A, NS5A inhibitor, hepatitis C treatment
No comments:
Post a Comment